Tech Company Financing Transactions
Provention Bio Funding Round
On 6/27/2017, Provention Bio raised $28.4 million in Series A funding from JDRF T1D Fund, Johnson & Johnson Development Corporation and MDB Capital Group.
Transaction Overview
Company Name
Announced On
6/27/2017
Transaction Type
Venture Equity
Amount
$28,400,000
Round
Series A
Investors
Proceeds Purpose
Provention will utilize proceeds from the financing to advance its founding mission to reduce the high morbidity, mortality, patient suffering, and escalating costs of debilitating autoimmune and inflammatory diseases by developing drugs and technologies that intervene before the targeted disease begins, re-appears or progresses.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Broad St. 2nd Floor
Red Bank, NJ 07701
USA
Red Bank, NJ 07701
USA
Phone
Website
Email Address
Overview
Provention Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ashleigh Palmer
Chief Financial Officer
Andrew Drechsler
Chief Operating Officer
Eleanor Ramos
Chief Scientific Officer
Francisco Leon
VP - Bus. Development
Jason Hoitt
VP - General Counsel
Heidy King-Jones
Browse more venture capital transactions:
Prev: 6/27/2017: Homer Logistics venture capital transaction
Next: 6/27/2017: Autotalks venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs